Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Brain Metastasis From Epithelial-derived Tumors
NCT02669914Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2016
- Primary completion
- Sep 2017
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in brain metastases (3 cohorts), sponsored by Washington University School of Medicine. Primary endpoint: Overall Response Rate of Intracranial Disease. Started Sep 2016; status: terminated.
02
Drugs
durvalumab
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT02669914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669914.